© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#blood cancer

Yescarta, CAR-T, axicabtagene ciloleucel
CAR-T Therapy: Lifeline to A Cure?
Imbruvica Bests Chemotherapy for Older People With Leukemia
Blood Cancers 101

Try, Try Again: Can a Second Dose of CAR-T Cells Succeed When the First Fails?

First-of-its-kind study offers early indication of factors linked to increased odds of success for patients out of options.
Multiple myeloma cells

CAR-T Therapies for Multiple Myeloma Show High Response Rates

90% to 100% of study participants achieved complete or partial responses to treatment.
Red and white blood cells

FDA Approves New Treatment for Chronic Lymphocytic Leukemia

Calquence is the second therapy approved under a new program that lets companies simultaneously apply for approval in multiple countries.
Motoko Koyama, MD, PhD

Mystery Solved: How Graft-Versus-Host Disease Starts in the Gut

Microbiome triggers top killer after bone marrow transplant — and there’s a potential way to stop it

Blood Cancer Awareness Month

September was designated as National Blood Cancer Awareness Month in 2010 by United States Congress.

That’s a Lot of Cancer

September is the awareness period of a whopping total of seven cancers. Seven!

Scientists Take First Step Toward Using CRISPR to Cure HIV in Humans

Trying to mimic the “Berlin Patient” cure, researchers edited the CCR5 gene in the immune stem cells of a man with leukemia and HIV.

September

I really have no idea how one should properly celebrate the month of one’s cancer.

Why Are Liver Disease Mortality Trends Shifting?

Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.

Multiple Myeloma

Cancer Health Focus

David Tracy received an experimental drug for BPDCN, a rare blood cancer, which is now part of standard therapy for the disease. The initial lesions on his back and chest are mostly gone or fading.

Researchers Making Headway on Treatment for Rare Blood Cancer

The trial is testing an experimental drug that targets one of the malignant immune cells that are a hallmark of the disease.
T cells attacking cancer cell

CAR T Cells Survive by Going Undercover

The researchers are now designing a first-in-human clinical trial to test the effectiveness of this approach in patients.

Cancer Awareness Months and Days

Shingles More Likely to Develop in People With Cancer

But new vaccines hold promise for prevention.
Damian Green, MD, presented the first results from his trial of genetically engineered immune cells for multiple myeloma. Green says this type of treatment could “dramatically alter the landscape in terms of how we manage multiple myeloma.”

‘Exciting’ but Early Results in Trial of Immunotherapy for Myeloma

Cancer cells disappeared rapidly in patients with high-risk, treatment-resistant disease.
Advertisement
Treatment News
Features